REPLY
23.10.2018 13:02:04 CEST | Business Wire | Press release
Today Oracle awarded Business Reply with its 2018 Oracle Excellence Award for Specialized Partner of the Year – EMEA in ERPM Cloud.
The Oracle Excellence Awards for Specialized Partner of the Year – EMEA recognizes Business Reply for their outstanding work in driving customer success with ERP Cloud offering. Oracle partners accelerate innovation and customers upgrade to the cloud. From business planning and implementation, to connectivity and data center services, Oracle PartnerNetwork (OPN) members provide the support and services needed to maximize the value of Oracle Cloud solutions for customers’ organization, and it offers its members unique opportunities to accelerate and expand their business.
Business Reply is a Platinum Cloud Select level member of Oracle PartnerNetwork (OPN). Business Reply was presented the 2018 Oracle Excellence Award for Specialized Partner of the Year – EMEA in ERPM Cloud for demonstrating an outstanding and innovative solution based on Oracle products.
The Oracle Excellence Awards for Specialized Partner of the Year – EMEA encourages innovation by Oracle PartnerNetwork (OPN) members, who use Oracle’s products and technology to create value for customers and generate new business potential.
Business Reply, the Reply Group company focused on Oracle SAAS, has been able to see the advantages of the Cloud in time and it has helped European companies to grasp the potential of the cloud, giving life to ambitious ERP cloud projects able to transform the business and services in depth.
Business Reply represents a point of reference among companies for ERP and Corporate Governance services, and it guarantees a deep knowledge of business processes together with a strong technical expertise on all Oracle application solutions.
Filippo Rizzante, CTO at Reply, said, “We are absolutely delighted to have won the award for Specialized Partner of the Year: ERPM Cloud – EMEA. Continuous investments in innovation and research & development have been critical to the creation of the most innovative ERP Cloud projects on Oracle technologies. The relationship and collaboration with Oracle has been instrumental to the success of Business Reply, enabling the team to maintain innovation as the Oracle platform evolves.”
“Business Reply has demonstrated an outstanding level of innovation in delivering proven, Oracle-based ERP Cloud solutions that solve our joint customers’ most critical business challenges,” said Javier Torres, Vice President Alliances & Channels Oracle EMEA. “We congratulate Business Reply in achieving the 2018 Oracle Excellence Award for Specialized Partner of the Year – EMEA in ERPM Cloud. This achievement is a testament to their dedication to excellence and to providing customers solutions that drive real business value and results.”
About Business Reply
Business Reply, the Reply Group company specialising in the creation of integrated systems based on Oracle application suites, is Oracle Platinum Cloud Select Partner. With over 18 years of experience and more than 80 completed projects, Business Reply represents a point of reference among companies for ERP and Corporate Governance services. Strongly oriented towards Digital Transformation, thanks to investments in innovation and research & development and a process of continuous training and specialization of its resources, Business Reply was the first Italian Oracle Partner to realize projects on Oracle ERP Cloud, OTM Cloud and Service Cloud. In 2018, Business Reply has been recognized by Oracle: “Cloud Excellence Implementer”, for providing superior customer experience through successful Oracle HCM Cloud Services implementations.
About Oracle PartnerNetwork
Oracle PartnerNetwork (OPN) is Oracle's partner program that provides partners with a differentiated advantage to develop, sell and implement Oracle solutions. OPN offers resources to train and support specialized knowledge of Oracle’s products and solutions and has evolved to recognize Oracle’s growing product portfolio, partner base and business opportunity. Key to the latest enhancements to OPN is the ability for partners to be recognized and rewarded for their investment in Oracle Cloud. Partners engaging with Oracle will be able to differentiate their Oracle Cloud expertise and success with customers through the OPN Cloud program – an innovative program that complements existing OPN program levels with tiers of recognition and progressive benefits for partners working with Oracle Cloud. To find out more visit: http://www.oracle.com/partners .
Trademarks
Oracle and Java are registered trademarks of Oracle and/or its affiliates.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181023005365/en/
Contact:
Reply Fabio Zappelli f.zappelli@reply.com or Aaron Miani a.miani@reply.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom